Targeting drug-resistant cell states to overcome standard therapy resistance

Lumaros is currently developing the targeted therapy of choice in NRAS mutant melanoma

Non-genetic plasticity of cancer cells allows adaptation and resistance formation against current therapies

Laboratory Scientist

Lumaros is developing novel drug classes that target resistant cancer cell states

Microscope